Evidence map›Paper›PMID 39841349›Full record

ArticleBreast cancer research and treatment2025

Classifying the molecular subtype of breast cancer using vision transformer and convolutional neural network features.

Chiharu Kai, Hideaki Tamori, Tsunehiro Ohtsuka, Miyako Nara, Akifumi Yoshida, Ikumi Sato, Hitoshi Futamura, Naoki Kodama, Satoshi Kasai

Abstract read
PubMed Publisher
In one paragraph

Article in Breast cancer research and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Chiharu KaiDepartment of Radiological Technology, Faculty of Medical Technology, Niigata University of Health and Welfare, 1398 Shimamichou, Kita-Ku, Niigata, Japan.
Hideaki TamoriThe Asahi Shimbun Company, Tokyo, Japan.
Tsunehiro OhtsukaOhtsuka Breastcare Clinic, Tokyo, Japan.
Miyako NaraOhtsuka Breastcare Clinic, Tokyo, Japan.
Akifumi YoshidaDepartment of Radiological Technology, Faculty of Medical Technology, Niigata University of Health and Welfare, 1398 Shimamichou, Kita-Ku, Niigata, Japan.
Ikumi SatoMajor in Health and Welfare, Graduate School of Niigata, University of Health and Welfare, Niigata, Japan.
Hitoshi FutamuraKONICA MINOLTA, INC, Tokyo, Japan.
Naoki KodamaDepartment of Radiological Technology, Faculty of Medical Technology, Niigata University of Health and Welfare, 1398 Shimamichou, Kita-Ku, Niigata, Japan.
Satoshi KasaiDepartment of Radiological Technology, Faculty of Medical Technology, Niigata University of Health and Welfare, 1398 Shimamichou, Kita-Ku, Niigata, Japan. satoshi-kasai@nuhw.ac.jp.

Funding

Japan Society for the Promotion of Science JP23K10899
6 · The paper itself

Abstract

purposeIdentification of the molecular subtypes in breast cancer allows to optimize treatment strategies, but usually requires invasive needle biopsy. Recently, non-invasive imaging has emerged as promising means to classify them. Magnetic resonance imaging is often used for this purpose because it is three-dimensional and highly informative. Instead, only a few reports have documented the use of mammograms. Given that mammography is the first choice for breast cancer screening, using it to classify molecular subtypes would allow for early intervention on a much wider scale. Here, we aimed to evaluate the effectiveness of combining global and local mammographic features by using Vision Transformer (ViT) and Convolutional Neural Network (CNN) to classify molecular subtypes in breast cancer.

methodsThe feature values for binary classification were calculated using the ViT and EfficientnetV2 feature extractors, followed by dimensional compression via principal component analysis. LightGBM was used to perform binary classification of each molecular subtype: triple-negative, HER2-enriched, luminal A, and luminal B.

resultsThe combination of ViT and CNN achieved higher accuracy than ViT or CNN alone. The sensitivity for triple-negative subtypes was very high (0.900, with F-value = 0.818); whereas F-value and sensitivity were 0.720 and 0.750 for HER2-enriched, 0.765 and 0.867 for luminal A, and 0.614 and 0.711 for luminal B subtypes, respectively.

conclusionFeatures obtained from mammograms by combining ViT and CNN allow the classification of molecular subtypes with high accuracy. This approach could streamline early treatment workflows and triage, especially for poor prognosis subtypes such as triple-negative breast cancer.

Indexed as

Breast NeoplasmsNeural Networks, ComputerBiomarkers, TumorConvolutional Neural NetworksErb-b2 Receptor Tyrosine KinasesFemaleHumansMammographyBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesArtificial intelligenceBreast cancerConvolutional neural networkMammogramMolecular subtypeVision transformer

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.